2 255

Cited 8 times in

Fludarabine, cytarabine, and attenuated-dose idarubicin (m-FLAI) combination therapy for elderly acute myeloid leukemia patients

DC FieldValueLanguage
dc.contributor.author민유홍-
dc.contributor.author정준원-
dc.date.accessioned2014-12-18T08:38:39Z-
dc.date.available2014-12-18T08:38:39Z-
dc.date.issued2013-
dc.identifier.issn0361-8609-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/86689-
dc.description.abstractWe performed a phase II trial to evaluate the efficacy and safety of the modified fludarabine, cytarabine, and attenuated-dose idarubicin (m-FLAI) regimen in elderly acute myeloid leukemia (AML) patients. Elderly (≥60 years) AML patients who had not previously received chemotherapy were enrolled in the study. Patients received two consecutive cycles of m-FLAI chemotherapy as an induction. The m-FLAI regimen comprised fludarabine (25 mg/m(2) , days 1-4), cytarabine (1,000 mg/m(2) , days 1-4), and attenuated-dose idarubicin (5 mg/m(2) , days 1-3). The primary end point was complete remission (CR) rate. Secondary end points were overall survival (OS), event-free survival (EFS), and treatment-related mortality (TRM). There were 108 patients (median age 68.4 years, M:F = 64:44) enrolled in the study. CR was achieved in 56.5% of patients, and the TRM rate was 21.3%. Median OS and median EFS were 10.2 and 6.6 months, respectively. The mortality at 30 and 60 days was 15 and 21%, respectively. Performance status and comorbidity did not have prognostic value in this patient cohort. Bone marrow expression of CD117 was associated with increased EFS and OS. m-FLAI is an effective induction regimen for previously untreated AML in elderly patients. In addition, bone-marrow CD117 expression is an independent favorable prognostic factor in elderly AML patients. (ClinicalTrials.gov number, NCT01247493).-
dc.description.statementOfResponsibilityopen-
dc.relation.isPartOfAmerican Journal of Hematology-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/2.0/kr/-
dc.subject.MESHAged-
dc.subject.MESHAged, 80 and over-
dc.subject.MESHAntineoplastic Combined Chemotherapy Protocols/administration & dosage*-
dc.subject.MESHAntineoplastic Combined Chemotherapy Protocols/adverse effects-
dc.subject.MESHBone Marrow/metabolism*-
dc.subject.MESHCohort Studies-
dc.subject.MESHCytarabine/administration & dosage-
dc.subject.MESHCytarabine/adverse effects-
dc.subject.MESHDisease-Free Survival-
dc.subject.MESHFemale-
dc.subject.MESHGene Expression Regulation, Leukemic*-
dc.subject.MESHHumans-
dc.subject.MESHIdarubicin/administration & dosage-
dc.subject.MESHIdarubicin/adverse effects-
dc.subject.MESHLeukemia, Myeloid, Acute*/drug therapy-
dc.subject.MESHLeukemia, Myeloid, Acute*/metabolism-
dc.subject.MESHLeukemia, Myeloid, Acute*/mortality-
dc.subject.MESHMale-
dc.subject.MESHMiddle Aged-
dc.subject.MESHProto-Oncogene Proteins c-kit/biosynthesis*-
dc.subject.MESHSurvival Rate-
dc.subject.MESHTime Factors-
dc.subject.MESHVidarabine/administration & dosage-
dc.subject.MESHVidarabine/adverse effects-
dc.subject.MESHVidarabine/analogs & derivatives-
dc.titleFludarabine, cytarabine, and attenuated-dose idarubicin (m-FLAI) combination therapy for elderly acute myeloid leukemia patients-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Internal Medicine (내과학)-
dc.contributor.googleauthorInho Kim-
dc.contributor.googleauthorYoungil Koh-
dc.contributor.googleauthorSung-Soo Yoon-
dc.contributor.googleauthorSeonyang Park-
dc.contributor.googleauthorByoung Kook Kim-
dc.contributor.googleauthorDae-Young Kim-
dc.contributor.googleauthorJung-Hee Lee-
dc.contributor.googleauthorKyoo-Hyung Lee-
dc.contributor.googleauthorJune-Won Cheong-
dc.contributor.googleauthorHong-Kee Lee-
dc.contributor.googleauthorSung-Hyun Kim-
dc.contributor.googleauthorHyuk Kim-
dc.contributor.googleauthorYoung Don Joo-
dc.contributor.googleauthorSang-Min Lee-
dc.contributor.googleauthorJong-Ho Won-
dc.contributor.googleauthorSung-Kyu Park-
dc.contributor.googleauthorDae-Sik Hong-
dc.contributor.googleauthorSe-Hyung Kim-
dc.contributor.googleauthorSang Kyun Sohn-
dc.contributor.googleauthorChul-Soo Kim-
dc.contributor.googleauthorEunkyung Park-
dc.contributor.googleauthorMin Kyoung Kim-
dc.contributor.googleauthorMoo Rim Park-
dc.contributor.googleauthorJe-Hwan Lee-
dc.contributor.googleauthorYoo Hong Min-
dc.identifier.doi10.1002/ajh.23337-
dc.admin.authorfalse-
dc.admin.mappingfalse-
dc.contributor.localIdA01407-
dc.contributor.localIdA03729-
dc.relation.journalcodeJ00085-
dc.identifier.pmid23077109-
dc.identifier.urlhttp://onlinelibrary.wiley.com/doi/10.1002/ajh.23337/abstract;jsessionid=D00C7A38C0DAF6C87242A7BB4C5F513D.f04t03-
dc.subject.keywordAged-
dc.subject.keywordAged, 80 and over-
dc.subject.keywordAntineoplastic Combined Chemotherapy Protocols/administration & dosage*-
dc.subject.keywordAntineoplastic Combined Chemotherapy Protocols/adverse effects-
dc.subject.keywordBone Marrow/metabolism*-
dc.subject.keywordCohort Studies-
dc.subject.keywordCytarabine/administration & dosage-
dc.subject.keywordCytarabine/adverse effects-
dc.subject.keywordDisease-Free Survival-
dc.subject.keywordFemale-
dc.subject.keywordGene Expression Regulation, Leukemic*-
dc.subject.keywordHumans-
dc.subject.keywordIdarubicin/administration & dosage-
dc.subject.keywordIdarubicin/adverse effects-
dc.subject.keywordLeukemia, Myeloid, Acute*/drug therapy-
dc.subject.keywordLeukemia, Myeloid, Acute*/metabolism-
dc.subject.keywordLeukemia, Myeloid, Acute*/mortality-
dc.subject.keywordMale-
dc.subject.keywordMiddle Aged-
dc.subject.keywordProto-Oncogene Proteins c-kit/biosynthesis*-
dc.subject.keywordSurvival Rate-
dc.subject.keywordTime Factors-
dc.subject.keywordVidarabine/administration & dosage-
dc.subject.keywordVidarabine/adverse effects-
dc.subject.keywordVidarabine/analogs & derivatives-
dc.contributor.alternativeNameMin, Yoo Hong-
dc.contributor.alternativeNameCheong, June Won-
dc.contributor.affiliatedAuthorMin, Yoo Hong-
dc.contributor.affiliatedAuthorCheong, June-Won-
dc.rights.accessRightsnot free-
dc.citation.volume88-
dc.citation.number1-
dc.citation.startPage10-
dc.citation.endPage15-
dc.identifier.bibliographicCitationAmerican Journal of Hematology, Vol.88(1) : 10-15, 2013-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.